glp 1 anorexia GLP-1 medications are changing the conversation around weight and health, but what about eating disorder risk? Join us for our 30-minute May Micro Learning Session: The GLP-1 Era: Navigating Weight Loss Drugs GLP-1 Medications and Eating Disorders:

Hormones and Behavior

The effects of GLP-1 analogues in obese, insulin-using type 2 diabetes in relation to eating behaviour

Science 299 (5603), 76

Indications and Limitations of Use Victoza (liraglutide) injection 1.2 mg or 1.8 mg is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes and to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes and established cardiovascular disease

A single plaintiff may have records spread across: Primary care physicians who prescribed the medication Pharmacies documenting fill dates and dosages Gastroenterologists performing diagnostic testing Emergency rooms treating acute symptoms Hospitals for surgical interventions Ophthalmologists for vision loss claims The court's mandate for objective diagnostic testing means incomplete GI specialist records can be case-ending

In 2025 so far, the FDA has received 379 reports of ischemic optic neuropathy associated with Ozempic, Wegovy, and semaglutide combined